Literature DB >> 24299502

Manufacturing and device options for the delivery of biotherapeutics.

Susan Hoe1, Mohammed A Boraey, James W Ivey, Warren H Finlay, Reinhard Vehring.   

Abstract

Biotherapeutic aerosol formulations are an intense area of interest for systemic and local drug delivery. This article provides a short overview of typical factors required specifically for biotherapeutic aerosol formulation design, the processing options open for consideration, and the issue of inhalation device selection. Focusing on spray drying, four case studies are used to highlight the relevant issues, describing investigations into: (1) the mechanical stresses occurring in bacteriophage formulations during spray-dryer atomization; (2) modeling of the spray-dryer process and droplet drying kinetics, to assist process design and predictions of formulation stability; (3) a predictive approach to the design and processing of a five-component dry powder aerosol formulation; and (4) the survival of bacteriophages after pressurized metered dose inhaler atomization.

Entities:  

Keywords:  bacteriophages; biotherapeutics; droplet drying kinetics; dry powder inhaler; metered dose inhaler; predictive approach; process modeling; spray drying

Mesh:

Year:  2013        PMID: 24299502     DOI: 10.1089/jamp.2013.1090

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  7 in total

Review 1.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

2.  Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.

Authors:  Nicholas B Carrigy; Rachel Y Chang; Sharon S Y Leung; Melissa Harrison; Zaritza Petrova; Welkin H Pope; Graham F Hatfull; Warwick J Britton; Hak-Kim Chan; Dominic Sauvageau; Warren H Finlay; Reinhard Vehring
Journal:  Pharm Res       Date:  2017-06-23       Impact factor: 4.200

3.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

4.  Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.

Authors:  Nicholas B Carrigy; Sasha E Larsen; Valerie Reese; Tiffany Pecor; Melissa Harrison; Philip J Kuehl; Graham F Hatfull; Dominic Sauvageau; Susan L Baldwin; Warren H Finlay; Rhea N Coler; Reinhard Vehring
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

Review 5.  Phage therapy of pulmonary infections.

Authors:  Stephen T Abedon
Journal:  Bacteriophage       Date:  2015-04-18

Review 6.  Inhalation drug delivery devices: technology update.

Authors:  Mariam Ibrahim; Rahul Verma; Lucila Garcia-Contreras
Journal:  Med Devices (Auckl)       Date:  2015-02-12

Review 7.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.